- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- January 2026
- 181 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 189 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- November 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- July 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- January 2026
- 197 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 189 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 188 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- August 2025
- 198 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 180 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- April 2025
Global
From €4292EUR$4,900USD£3,725GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 553 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP

Budesonide is a corticosteroid used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. It is available in both inhalation and oral forms, and is used to reduce inflammation in the airways. Budesonide is a synthetic corticosteroid, meaning it is similar to the hormones produced naturally by the body. It works by reducing inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath.
Budesonide is a widely used drug in the respiratory market, and is often prescribed as a first-line treatment for asthma and COPD. It is generally well-tolerated and has fewer side effects than other corticosteroids. It is also used in combination with other drugs to treat more severe cases of respiratory diseases.
Some companies in the Budesonide market include AstraZeneca, GlaxoSmithKline, Merck, and Teva Pharmaceuticals. Show Less Read more